Skip to main content
Công ty Cổ phần Dược phẩm Imexpharm logo

Công ty Cổ phần Dược phẩm Imexpharm — Investor Relations & Filings

Ticker · IMP ISIN · VN000000IMP0 HSX Manufacturing
Open in API
Filings indexed 381 across all filing types
Latest filing 2024-07-10 Share Issue/Capital Cha…
Country VN Viet Nam
Listing HSX IMP

About Công ty Cổ phần Dược phẩm Imexpharm

www.imexpharm.com

Imexpharm Corporation is a prominent pharmaceutical company with over 48 years of experience in the manufacturing, compounding, and distribution of high-quality pharmaceutical products. The company operates extensive production facilities, including three EU-GMP certified factory clusters and one WHO-GMP certified cluster, making it a leader in EU-GMP compliant manufacturing. Imexpharm is recognized as a top producer of antibiotics and offers a diverse product portfolio encompassing injectable and oral antibiotics, cardiovascular, ophthalmic, musculoskeletal, respiratory, and digestive system treatments, alongside vitamins, minerals, and health protection foods. With 28 product registrations for 11 products in Europe, Imexpharm is dedicated to delivering effective and safe healthcare solutions to the community.

Recent filings

Filing Released Lang Actions
IMP: Nghị quyết HĐQT về việc lấy ý kiến cổ đông bằng văn bản
Share Issue/Capital Change Classification · 82% confidence The document is a formal disclosure to the State Securities Commission and Ho Chi Minh Stock Exchange of Board of Directors resolutions regarding the issuance of new shares to increase charter capital and the implementation of an ESOP plan for key personnel. It contains detailed terms of the share issuance (bonus shares and ESOP) and is clearly a corporate action affecting the company’s capital structure rather than an earnings release, management discussion, or proxy material. This aligns with our Share Issue/Capital Change category (SHA).
2024-07-10 Vietnamese
IMP: CBTT Nghị quyết HĐQT về việc lấy ý kiến cổ đông bằng văn bản
Share Issue/Capital Change Classification · 90% confidence The document is a regulatory disclosure of a Board of Directors’ resolution relating to the issuance of new shares for capital increase from owner’s equity and an ESOP plan, including detailed terms of the share issuance, timing, quantity, purpose and related corporate actions. This is a clear announcement of a share issue/capital change rather than an earnings release, report, transcript or other category. Therefore, it fits the Share Issue/Capital Change category.
2024-07-05 Vietnamese
IMP: Thông báo về ngày ĐKCC chi trả cổ tức năm 2023 bằng tiền và cổ phiếu
Notice of Dividend Amount Classification · 92% confidence The document is a stock exchange notice from Ho Chi Minh City’s bourse announcing the ex-dividend date, record date, dividend rates (cash and stock), payment dates, and procedures for shareholders. This matches the definition of a Notice of Dividend Amount (Code: DIV).
2024-07-02 Vietnamese
IMP: Thông báo phát hành cổ phiếu để trả cổ tức năm 2023
Share Issue/Capital Change Classification · 95% confidence The document is an official disclosure to the State Securities Commission and Ho Chi Minh Stock Exchange describing the plan and details for Imexpharm’s issuance of new shares to pay the 2023 dividend in stock. It provides issuance ratios, total number of shares, source of funds, registration dates, and other capital change details – fitting the “Share Issue/Capital Change” category.
2024-06-28 Vietnamese
IMP: Thông báo ngày ĐKCC để thực hiện quyền nhận cổ tức năm 2023 bằng tiền và cổ phiếu
Notice of Dividend Amount Classification · 94% confidence The document is a formal regulatory disclosure to the State Securities Commission, HOSE and VSDC announcing the record date (“ngày đăng ký cuối cùng”) to exercise rights to receive 2023 dividends in cash and shares, specifying dividend ratios, payment dates and procedures. It is neither a financial report nor a management discussion but a dividend notice. According to the filing definitions, this is a Notice of Dividend Amount (DIV).
2024-06-28 Vietnamese
IMP: Nghị quyết HĐQT về việc chốt danh sách cổ đông để thực hiện quyền nhận cổ tức năm 2023 bằng tiền và cổ phiếu
Notice of Dividend Amount Classification · 87% confidence The document is an official disclosure by Imexpharm Corporation announcing the record date for 2023 dividend entitlement and providing detailed terms of the dividend payment (cash payout ratio, payment date, stock dividend ratio, handling of fractional shares). This matches the definition of a Notice of Dividend Amount (DIV). It is not an AGM material, financial report, or management change but specifically details dividend distribution.
2024-06-28 Vietnamese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.